UnitedHealth Shares Slide 0.3% on 15th-Highest Trading Volume Amid Analyst Split and Regulatory Scrutiny of Optum Division

On September 3, 2025, UnitedHealth (UNH) declined 0.30% with a trading volume of $2.96 billion, ranking 15th in market activity. Analysts remain divided on the stock, with 15 "buy" ratings and three "sell" recommendations from 24 Wall Street analysts. The average 12-month price target stands at $353.00, implying a 14.88% potential upside from its current level. Recent downgrades from Cantor Fitzgerald, Bank of America, and others highlight growing caution, while bullish analysts cite UnitedHealth’s diversified healthcare operations and 12.9% year-over-year revenue growth as strengths.

Despite the mixed analyst sentiment, institutional ownership of 87.86% underscores significant stakeholder confidence. However, risks persist, including a debt-to-equity ratio of 0.73 and recent insider selling. Notable investors like Warren Buffett and Michael Burry have increased their holdings, suggesting perceived undervaluation. UnitedHealth’s Optum division faces regulatory scrutiny, including a DOJ review of its pharmacy services, which could impact investor sentiment.

Backtest data reveals a 14.88% projected upside based on analyst consensus, with price targets ranging from $198 to $675. The stock’s moderate buy rating reflects optimism about long-term healthcare demand but acknowledges near-term challenges. Institutional investors and analysts appear to balance growth potential against regulatory and operational risks in their evaluations.